Akorn-Strides introduces rifampin for injection

The joint venture expects to generate immediate revenue from rifampin launch and from several other new product launches in the second half of 2008.

Rifampin is used in the treatment of all forms of tuberculosis in conjunction with Isoniazid and Ethambutol.

Akorn and Strides have previously formed a joint venture in 2004. The primary mission for the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics, anti-emetics and central nervous system medicines.

Arthur Przybyl, president and CEO of Akorn, said: “We look forward to the joint venture contributing positive operating results for both Akorn and Strides Arcolab in the near future.”